Medical Technology-P (09996) is now down by more than 8%, as of press time, down 6.2%, at HKD 2.42, with a turnover of 68.66 million Hong Kong dollars.
According to the Wisdom Financial App, Medical Technology-P (09996) is now down by more than 8%, as of press time, down 6.2%, at HKD 2.42, with a turnover of 68.66 million Hong Kong dollars.
On the news front, Medical Technology announced that its six-month revenue at the end of June was about RMB 2.9 billion to 3.1 billion, a year-on-year increase of 28.9%-37.8%. This is mainly due to the accelerated commercialization of its endovascular aortic valve replacement product, further expanding the group's market share, and a significant increase in the sales volume of the group's spring coil product, among other factors. In addition, the company sold about 1.91% of its stake in JenaValve, with expected pre-tax sales proceeds of USD 5.1 million.
Bank of China International pointed out that the company's first-half revenue growth was slightly lower than expected. The bank has lowered its short- to long-term revenue growth expectations to reflect factors such as the slowdown in market growth, with a year-on-year growth rate of only 20% for implants in the first half of the year and a reduction in the factory prices of first- and second-generation products. The bank noted that the implementation of DRGS 2.0 and the recovery of industry regulation are still dragging down the growth of the TAVR industry, and the market still needs time to rebuild its confidence in the commercialization of percutaneous valve products.